Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07423481

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Obesity & Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
  • No objection to the use of their data
  • Patients able to complete an online questionnaire (via the internet)

Exclusion criteria

  • Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection

Treatment and study plan

SEMAFOLLOW questionnaire

Other

If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes

Primary outcomes

  1. Describe weight changes during the follow-up period according to patient characteristics.

    Time frame: Baseline

Secondary outcomes

  1. Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.

    Time frame: Baseline

  2. Compare the profiles of responders and non-responders

    Time frame: Baseline

  3. Describe weight change according to different subpopulations.

    Time frame: Baseline

Study contacts

Contact information is provided by the study sponsor or research team.

David JACOBI

CONTACT

[email protected]

+332 53 48 28 35

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Collaborators

  • Novo Nordisk A/S

Registry information

Official study title

SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France

Acronym: SEMAFOLLOW

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 20, 2026
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.